author = {Nomoto, Hiroshi. and Miyoshi, Hideaki. and Nakamura, Akinobu. and Atsumi, Tatsuya. and Manda, Naoki. and Kurihara, Yoshio. and Aoki, Shin. and , on behalf of SAIS Study Group.}, title = {{Impact of incretin-related agents on endothelial cell function}}, journal ={Clinical Trials in Degenerative Diseases}, volume ={2}, number ={1}, pages = {7-11}, doi = {10.4103/2542-3975.202726}, year = {2017}, abstract ={Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence.}, URL ={https://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2017;volume=2;issue=1;spage=7;epage=11;aulast=Nomoto;t=6}, eprint ={https://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2017;volume=2;issue=1;spage=7;epage=11;aulast=Nomoto;t=6} }